RNTX Rein Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNTX

Price (delayed)

$0.7913

Market cap

$67.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.9

Enterprise value

$68.17M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6
Highlights
The EPS is up by 40% year-on-year and by 3.1% since the previous quarter
Rein Therapeutics's net income has increased by 18% YoY
Rein Therapeutics's equity has shrunk by 77% YoY and by 31% QoQ
RNTX's quick ratio has shrunk by 73% YoY and by 37% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aileronrx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RNTX

RNTX stock price

How has the Rein Therapeutics stock price performed over time
Intraday
-1.1%
1 week
-8.21%
1 month
-21.65%
1 year
-44.27%
YTD
-31.78%
QTD
-23.91%

Financial performance

How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$50.25M
Net income
-$50.21M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 21% year-on-year
Rein Therapeutics's net income has increased by 18% YoY

Price vs fundamentals

How does RNTX's price correlate with its fundamentals

Growth

What is Rein Therapeutics's growth rate over time

Valuation

What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 40% year-on-year and by 3.1% since the previous quarter
RNTX's P/B is 112% above its 5-year quarterly average of 0.9 and 27% above its last 4 quarters average of 1.5
Rein Therapeutics's equity has shrunk by 77% YoY and by 31% QoQ

Efficiency

How efficient is Rein Therapeutics business performance
The ROE has plunged by 101% YoY and by 32% from the previous quarter
The ROA has plunged by 69% YoY and by 20% from the previous quarter

Dividends

What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNTX.

Financial health

How did Rein Therapeutics financials performed over time
The company's total assets is 79% higher than its total liabilities
The total liabilities has soared by 103% from the previous quarter and by 90% YoY
RNTX's quick ratio has shrunk by 73% YoY and by 37% QoQ
The debt is 58% smaller than the equity
Rein Therapeutics's equity has shrunk by 77% YoY and by 31% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.